We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01219582
Previous Study | Return to List | Next Study

GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients (GLOBE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01219582
Recruitment Status : Completed
First Posted : October 13, 2010
Last Update Posted : November 13, 2013
Information provided by (Responsible Party):

Brief Summary:
An observational and multicenter study to assess the effectiveness and safety of Glucobay®- M under daily life treatment of type-2 diabetes patients.The study objectives are to investigate the effectiveness and safety of Glucobay® -M on blood glucose and patients body - weight. Glucobay®- M is taken 1-3 times daily. All patients with type 2 diabetes mellitus, where investigator feels that addition of Glucobay®-M would be beneficial to patients will be included in non- interventional study. The routine investigation suggested by the attending physician will be done in diabetic patients. No additional investigation will be done for the study purpose. The uncontrolled diabetic patient on existing treatment and prescribed Glucobay®-M will be included in study after taking the informed consent. The patient will be asked to attend 2 follow up visit each after 6 weeks. All patients receiving at least one tablet will be included in the safety analysis.The study is planned to be carried out in 10000 patients from 320-350 trial sites in India.

Condition or disease Intervention/treatment
Type 2 Diabetes Drug: Glucobay M (Acarbose/Metformin, BAY81-9783)

Layout table for study information
Study Type : Observational
Actual Enrollment : 9364 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Open, Prospective, Multicentric, Single-arm, Non-interventional Study to Evaluate the Effectiveness & Safety of Oral Glucobay®-M Tablets in Type 2 Diabetes Patient
Study Start Date : October 2010
Actual Primary Completion Date : January 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Group 1 Drug: Glucobay M (Acarbose/Metformin, BAY81-9783)
Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.

Primary Outcome Measures :
  1. Change in fasting blood glucose levels [ Time Frame: 12 weeks ]
  2. Change in post-prandial glucose values [ Time Frame: 12 weeks ]
  3. Change in Hemoglobin A1c (HbA1c) levels [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Number of patient with adverse events [ Time Frame: 12 weeks ]
  2. Percentage of patients with satisfaction of treatment [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Type 2 Diabetes

Inclusion Criteria:

  • Female and male patients ≥ 18 years of age with Type 2 Diabetes where investigator feels that addition of Glucobay®-M would be beneficial to patients.
  • The diagnosis will be made based on the ADA criteria by the attending physician.
  • Patients will be defined as included in the study if they have a documented prescription of Glucobay-M by the physician.
  • Patients willing to provide signed & dated informed consent.
  • Patients willing to comply with study requirements.

Exclusion Criteria:

  • According to the local product information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01219582

Layout table for location information
Many Locations, India
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01219582    
Other Study ID Numbers: 14954
GB0910IN ( Other Identifier: company internal )
First Posted: October 13, 2010    Key Record Dates
Last Update Posted: November 13, 2013
Last Verified: November 2013
Keywords provided by Bayer:
Diabetes Mellitus Type-2
Drug Therapy, Combination
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Glycoside Hydrolase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action